Jaguar Health, Inc. (JAGX): Entry into a Material Definitive Agreement
Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 d570985dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of June 9, 2026 (this “ Agreement ”), by and among C/M Capital Partners, LP, a [ ] limited liability company (the “ Investor ”
How this was made
The 30-second read
Why it matters
This is a financing structure that permits the company to sell common stock to the investor from time to time during the investment period, up to a maximum dollar amount and share ownership cap, with pricing tied to eligible-market closing/VWAP references.
Market read
New equity purchase facility disclosure can reprice dilution expectations and increase trading volatility for JAGX as drawdown activity begins.
What to watch
Traders should monitor whether stockholder approval is required/obtained for any issuance beyond 19.99% and how quickly the company files subsequent notices/drawdowns under the facility.
Background
The 8-K reports entry into a Common Stock Purchase Agreement (Exhibit 10.1) with C/M Capital Partners, plus concurrent registration rights for shares issued under the facility.
Ticker impact
Jaguar Health entered a common stock purchase agreement allowing sales up to $40M and 19.99% of outstanding shares to C/M Capital Partners.
Bias toward downside/volatility around execution and any subsequent drawdowns, especially if purchases occur below recent trading levels.
8-K Exhibit 10.1 details an equity purchase facility with capped size and pricing mechanics tied to market/VWAP, implying dilution over the investment period if the company elects to sell.
Market effects
Adds another example of small-cap biotech/healthcare using structured equity purchase agreements, reinforcing dilution/financing overhang risk in the group.
Primarily impacts US small-cap risk appetite and microcap liquidity flows.
Limited direct global spillover; mostly company-specific financing/dilution dynamics.
Counterpoint
If the company draws minimally (or only at/near market per the agreement’s pricing conditions), dilution impact could be smaller than feared.
Key entities
- issuerJaguar Health, Inc.
Company entering the common stock purchase agreement and issuing commitment shares and future drawdown shares.
- investorC/M Capital Partners, LP
Counterparty investor purchasing shares under the agreement up to the stated limits.
